Intraoperative Fractions of Inspiratory Oxygen Are Associated With Recurrence-Free Survival After Elective Cancer Surgery

Introduction

An increased fraction of inspiratory oxygen (FiO₂) is frequently used in anesthesia, intensive care, and emergency medicine. A concept of using 80 vs. 30% FiO₂ has been proposed for the prevention of surgical site infections (SSI) more than 20 years ago (1) and has been evaluated in several subsequent randomized controlled trials (RCTs) (1–3). Based on a systematic review and meta-analysis (4), the WHO and other societies (5–7) issued guidelines advocating the use of 80% FiO₂ during surgery. These recommendations have caused considerable concern, as the authors of other systematic reviews and meta-analyses arrive at opposing conclusions (8, 9) and because the relevance of potential oxygen-mediated side effects is still under debate (9, 10). In a post-hoc analysis of the PROXI trial, administration of 80% oxygen in the perioperative period was associated with increased long-term mortality in patients undergoing cancer surgery (11), and after a median follow-up of 3.9 years, cancer-free survival was significantly reduced in the 80% oxygen group compared with patients randomized to 30% FiO₂ (12). Outside of clinical trials and before the first WHO recommendation regarding supplemental oxygen (13) was published, intraoperative FiO₂ was typically used in the range of 30% to more than 90%, and the choice for the actual FiO₂ did depend on patients' requirements, type of surgical intervention, and anesthesiologist's preferences (14).

Currently, it is unknown whether the choice of higher or lower FiO₂ in a real-world setting outside of clinical trials is associated with long-term outcomes after cancer surgery. Therefore, we conducted a retrospective and exploratory study to evaluate the association of perioperative FiO₂ and recurrence-free survival after elective cancer surgery was performed before the WHO recommendation advocating supplemental oxygen for prevention of SSI was published.

Methods

Study Design and Population

We performed a retrospective and exploratory study in patients receiving general anesthesia for elective abdominal cancer surgery in the period from January 1, 2009, to December 31, 2016, at the Department of General-, Visceral-, and Transplant Surgery, Heidelberg University Hospital, Heidelberg, Germany. The study protocol conformed to the “Strengthening the Reporting of Observational studies in Epidemiology (STROBE)” guidelines (15), and the principles of the Declaration of Helsinki and was approved by the local Ethics Committee of the Medical Faculty of the Ruprecht-Karls-University, Heidelberg (S-326/2019, August 9, 2019). We assessed whether perioperative FiO₂ was associated with recurrence-free survival after surgery for three exemplary abdominal cancer entities. Patients with elective surgery of the pancreas, colon or rectum, or liver were included. Subgroup analysis was performed for the three tumor entities. Data were retrieved for all patients ≥ 18 years of age who underwent elective resection of pancreatic (PC), colorectal (CRC,) or hepatic cancer (HC) with R0 (no residual tumor) or R1 (microscopic residual tumor) resection, without distant metastases at the time of surgery, and with follow-up for at least 180 days. Exclusion criteria were intraoperative detection of peritoneal carcinomatosis or if histology analysis could not reveal cancer tissue i.e., after neoadjuvant chemo- or radiotherapy. Patients were also excluded if they suffered familial adenomatous polyposis or did receive home oxygen therapy in the preoperative period.

Data Collection

Baseline data retrieved from the prospectively maintained electronic pancreas, colorectal, and liver databases of the Department of Surgery at Heidelberg, University Hospital and from the electronic patient file were: demographic data, weight, height, body mass index (BMI), American Society of Anesthesiologists physical status classification (ASA), preexisting diseases including diabetes mellitus and chronic obstructive pulmonary disease (COPD), history of smoking, duration of surgery, need for postoperative ventilation, reintubation, use of epidural anesthesia, intraoperative dose of sufentanil, units of red blood cells (RBC), fresh frozen plasma (FFP), and platelet concentrates (PLT) transfused during surgery and during the entire hospital stay, use of intraoperative radiation therapy (IORT), neoadjuvant and adjuvant radio-, and chemotherapy. For colorectal and pancreatic cancer, tumor site was differentiated as follows: pancreatic head vs. body/tail cancer and rectal vs. colon cancer. Resection margin status, TNM (tumor, node, metastasis) classification, and tumor grading were retrieved from pathology reports. For every patient mean FiO₂ was calculated on the basis of the FiO₂ levels documented in the anesthesia protocol at 15-min intervals after induction of anesthesia (first 45 min) until extubation. Furthermore, the measurements of partial pressure of oxygen in arterial blood gases (paO₂) during surgery were collected. For outcome analyses, intensive care unit and hospital length of stay, date of local recurrence or occurrence of distant metastases, and date and cause of death were collected.

Outcome Analysis

The primary outcome measure was recurrence-free survival in the period from index surgery until the last known follow-up. Recurrence-free survival was defined as the time from index surgery to the first documented event of local cancer recurrence, newly diagnosed metastases, or death. Computer tomography, abdominal ultrasound, physical examination, and blood sampling were conducted in follow-up examinations at regular intervals or were prompted by new symptoms. If there was no diagnosis of cancer recurrence, new metastases, or death documented, the last date of follow-up or doctor–patient contact with negative findings was recorded. Secondary outcomes were overall survival, sepsis, reoperations due to surgical complications, SSI (superficial incisional, deep incisional, and organ space) and cardiovascular events (myocardial infarction, cerebral infarction, or transitory ischemic attack) during hospital stay were recorded.

Statistical Analysis

The entire patient cohort was sorted based on ascending mean intraoperative FiO₂ values and was then divided into two equal sized groups. The low-FiO₂ group and the high-FiO₂ group comprised 542 patients each. Descriptive analyses comprised calculation of mean, standard deviation (SD), median, and first and third quartile for continuous variables and absolute and relative proportions for categorical variables. The distribution of categorical variables in the different groups was compared using the chi-square test. Differences in continuous variables were evaluated using the Mann–Whitney U test. The primary survival analysis for the prespecified primary endpoint recurrence-free survival was performed using the Kaplan–Meier method (16) and groups were compared by means of the log-rank test (17). As the three tumor entities were not equally distributed over the low- and high-FiO₂ groups, and because the tumor entities analyzed in our study differed regarding long-term survival rates, we performed an additional analysis to control for tumor entity. First, within each of the three tumor entities, patients were sorted by ascending intraoperative mean FiO₂ values before patients were equally divided into a low- and high-FiO₂ group within each entity. Kaplan–Meier curves of these groups were compared within entities. Then patients from the three–tumor entity specific low-FiO₂ groups were combined into one-entity-controlled low-FiO₂ group, and patients from the three-tumor entity specific high-FiO₂ groups were combined in one entity-controlled high-FiO₂ group. These two groups were compared using a stratified log-rank test with the different tumor entities as strata. Thereafter, the primary outcome was analyzed within the tumor entities PC and CRC by the Cox proportional hazard model (18) in which the effect of mean FiO₂ on recurrence-free survival adjusted for the following covariates was estimated: gender, age, body mass index, nicotine use, diabetes mellitus, UICC (Tumor classification according to the Union for International Cancer Control) stage, tumor localization, tumor grading, resection margin status, use of epidural anesthesia, intraoperative dose of sufentanil, units of RBC, FFP, and PLT transfused during the entire hospital stay, intraoperative, neoadjuvant and adjuvant radio- and chemotherapy, and laparoscopic surgery in patients with CRC. If fentanyl was used as the opiate instead of sufentanil, the fentanyl dose was multiplied by a factor of 0.1 to calculate the equivalent sufentanil dose (19).

Mean FiO₂, age, PLT transfusion, intraoperative dose of sufentanil, and BMI are continuous variables, and the other variables are categorial. P-values of regression coefficients were obtained by the Wald-Test. Hazard ratios (HRs) estimated from the Cox analysis were reported with corresponding 95% CIs and a two-sided p < 0.05 was denoted as considerable. The HC-stratum was too small to fit a covariate-adjusted cox regression. The 1-year and 5-year overall survival was estimated by the Kaplan–Meier method. P-value is referred to the stratified log rank test with entities as strata.

Statistical analyses were performed using IBM SPSS Statistics 26.0 (SPSS, Chicago, IL) and Prism 9.0.0 (GraphPad Prism Software, Inc, San Diego, CA).

Results

Data from 1,214 patients were retrieved from databases. Datasets from 100 patients could not be assessed for eligibility because of incomplete or missing anesthesia records since the patient ID retrieved from the database did not match with a case in the hospital information system, or because the type of surgery was not eligible, i.e., non-tumor surgery. Considering exclusion criteria, 30 patients had to be excluded. Therefore, 1,084 patients were included in the final analysis set (Figure 1) with a median follow-up of 3.28 (Q1–Q3, 1.68–4.97) years.

FIGURE 1

Figure 1. Participant flow chart.

Patient Characteristics

Main clinical and demographical baseline characteristics are presented in Table 1 and the Supplementary Material. A total of 1,084 patients underwent elective PC (n = 652), CRC (n = 405), or HC surgery (n = 27). The mean age was 63 ± 11 years. Male participants were slightly more than female participants. At the time of surgery, the most common cancer stage was UICC 2 and the most common tumor grades were 1 and 2. Around 45% of patients' tumor resection margin status in the pathology report was classified as R1. In the majority of patients with PC, “pancreatic head” was found as the tumor localization; in the majority of patients with CRC “rectum” was found as the tumor localization. Patients received neoadjuvant chemotherapy or neoadjuvant radiotherapy in 15% of cases and 70% received adjuvant chemotherapy. IORT was conducted in 3%. General anesthesia was performed as balanced anesthesia except in four patients. In a small proportion (four patients (0.3%)), fentanyl was used instead of sufentanil and the corresponding equivalent dose was calculated. Intraoperative dose of sufentanil was slightly higher in the low-FiO₂-groups of patients with CRC and PC (CRC: 88.45 μg ± 45.04 vs. 80.12 μg ± 32.37; low vs. high-FiO₂, p = 0.012; PC: 80.86 μg ± 51.16 vs. 72.22 μg ± 42.85; low vs. high-FiO₂, p = 0.002; HC: 73.21 μg ± 42.23 vs. 66.92 μg ± 27.80; low- vs. high-FiO₂, p = 1.0). Epidural anesthesia was more common in the high-FiO₂-groups of patients with CRC and PC (CRC: 21(10%) vs. 39 (19%); low- vs. high-FiO₂, p = 0.011; PC: 230 (71%) vs. 258 (79%); low- vs. high-FiO₂, p = 0.011; HC: 10 (71%) vs. 10 (77%), p = 0.745). In total, 111 (10.2%) patients were transfused intraoperatively and 284 (26.2%) during their entire hospital stay. There was no difference between the entity-controlled low-FiO₂ and entity-controlled high-FiO₂ groups (intraoperative transfusion: 54 (9.9%) vs. 57 (10.5%); entity-controlled low-FiO₂ vs. entity-controlled high-FiO₂; p = 0.784; transfusions during entire hospital stay: 139 (25.6%) vs. 145 (26.8%); entity-controlled low-FiO₂ vs. entity-controlled high-FiO₂; p = 0.652).

TABLE 1

Table 1. Clinical baseline characteristics of the study cohort.

The average age was higher in the low-FiO₂ group (64 ± 10.5 vs. 62 ± 11 years, low- vs. high-FiO₂,p = 0.003). For none of the tumor entities, differences with regard to diabetes, history of smoking, or gender were detected. Also, for neither of the tumor entities we observed differences regarding tumor grading status, UICC stage, resection margin status, neoadjuvant, adjuvant therapy, or IORT. In PC surgery, tumor localization in the pancreatic head was more common in the low-FiO₂ group (81 vs. 72%, p = 0.009; low- vs. high-FiO₂). There was no difference in CRC patients with regard to tumor localization between both groups. In CRC surgery, open surgery was more common in the high-FiO₂ group (85 vs. 92%, p = 0.029; low- vs. high-FiO₂). PC and HC surgery were always performed as open surgery. Robotic surgery was not performed in our patient cohort. The proportions of the three tumor entities differed between the low and high-FiO₂ group (PC: 72.1%, CRC: 26.8%, HC: 1.1% vs. PC 48.2%, CRC 48.0%, HC 3.9%, p < 0.001; low- vs. high-FiO₂). The average duration of PC surgery was longer than the duration of CRC and HC surgery (PC:313 min ± 103, CRC 221 min ± 83, HC: 168 min ± 69, p < 0.001).

Observed FiO₂ and PaO₂

After dividing the cohort into low and high FiO₂ patients, the cut off value between the two groups was 45.1%, the median of patients' intraoperative FiO₂ mean [Q1; Q3] in the low-FiO₂ group was 40.9 [38.3; 42.9] vs. 50.4% [47.4; 54.7] in the high-FiO₂ group (Figure 2A). In CRC surgery, the calculated cut off value was 48.1%, the median of patients' FiO₂ means in the low-FiO₂ group was 42.8 [40.0; 45.6] vs. 53.1% [50.3; 58.6] in the high-FiO₂ group. In PC surgery, the calculated cut off value was 43.6%, the median of patients' FiO₂ means in the low-FiO₂ group was 39.8 [37.7; 41.8] vs. 47.9% [45.5; 52.1] in the high-FiO₂ group. In HC surgery, the calculated cut off value was 54.0%, the median of patients' FiO₂ means in the low-FIO₂ group was 45.5 [41.0; 47.9] vs. 60.2% [56.1; 62.8] in the high-FiO₂ group (Figure 2B).

FIGURE 2

Figure 2. Observed FiO₂. Data are presented as median (interquartile range). Whiskers indicate the minimum and maximum values. P-values were tested using the non-parametric Mann-Whitney U test. (A) Intraoperative FiO₂ levels of the low-FiO₂ group compared to the high-FiO₂ group. (B) Intraoperative FiO₂ levels of the low-FiO₂ groups and the high-FiO₂ groups of each entity. FiO₂, Fraction of inspired oxygen; CRC, Colorectal cancer; PC, Pancreatic cancer; HC, Hepatic cancer.

The mean paO₂ during surgery was significantly higher in the high-FiO₂ group (median of patients' intraoperative paO₂ mean: 172.7 mmHg [152.15; 193.05] vs. 200.7 mmHg [173.2; 235.8], low-vs. high-FiO₂) (Figure 3A). After stratifying for tumor entities, median paO₂ values were also significantly lower in the low-FiO₂ groups compared to the high-FiO₂ groups (CRC: Median of patients' intraoperative paO₂ mean: 167.9 mmHg [146.5; 188.0] vs. 190.0 mmHg [147.0; 217.5], low-vs.high-FiO₂; PC: Median of patients' intraoperative paO₂ mean: 172.38 mmHg [152.6; 190.3] vs. 203.4 mmHg [174.1; 230.0], low-vs. high-FiO₂; HC: Median of patients' intraoperative paO₂ mean: 197.0 mmHg [162.3; 214.3] vs. 238.33 mmHg [198.3; 296.4], low-vs. high-FiO₂) (Figure 3B).

FIGURE 3

Figure 3. Observed paO₂. Data are presented as median (interquartile range). Whiskers indicate the minimum and maximum values. P-values were tested using the non-parametric Mann-Whitney U test. (A) Intraoperative mean paO₂ levels of the low-FiO₂ group compared to the high-FiO₂ group. (B) Intraoperative mean paO₂ levels of the low-FiO₂ groups and the high-FiO₂ groups of each entity. paO₂, Arterial oxygen pressure; CRC, Colorectal cancer; PC, Pancreatic cancer; HC, Hepatic cancer.

Survival Analysis

In total, cancer recurrence between index surgery and last follow-up was diagnosed in 588 patients (54%). Among those patients, 136 (23.1%) experienced local recurrence and no distant metastases, 309 (52.5%) had distant metastases without local recurrence, and 133 patients (22.6%) suffered from both local relapse and distant metastases. For 10 patients (1.7%), information about the type of recurrence was not available. During the observation period, 402 patients (37.1%) died, mostly (381 cases) due to their malignant disease. Two patients died due to postoperative complications; four patients because of cardiovascular events after hospital discharge. In 15 patients, the cause of death was unknown. Recurrence-free survival was considerably higher in the high-FiO₂ group (log-rank-test: p < 0.001) (Figure 4). This effect was preserved in the entity-controlled groups. Recurrence-free survival was lower in the entity-controlled -low-FiO₂ group compared to the entity-controlled -high-FiO₂ group (stratified log rank test: p = 0.007) (Figure 5).

FIGURE 4

Figure 4. FiO₂ and recurrence-free survival. Patients were divided into low-FiO₂ group and high-FiO₂ group. The p-value was evaluated using the log-rank test (p < 0.001). FiO₂, Fraction of inspired oxygen.

FIGURE 5

Figure 5. FiO₂ and recurrence-free survival stratified for tumor entities. Patients were divided into an entity-controlled low-FiO₂ group and entity-controlled high- FiO₂ group. A stratified log-rank test with entities as strata was performed (p = 0.007). FiO₂, Fraction of inspired oxygen; CRC, Colorectal cancer; PC, Pancreatic cancer; HC, Hepatic cancer.

The cancer entity itself plays a relevant role in the average survival time of a patient (20–22). Therefore, we performed subgroup analyses for PC and CRC patients respectively using a Cox proportional hazard model, considering factors influencing the observed effect. These analyses revealed an independent association for mean FiO₂ and recurrence-free survival in patients undergoing CRC surgery (B = −0.035; p = 0.025). Recurrence-free survival was longer in patients with higher mean FiO₂. The hazard ratio (HR) for the variable mean FiO₂ was 0.965, and thus, HR is 0.965⁵ = 0.837 between two patients whose mean FiO₂ differ by 5%; per 1% rise of mean FiO₂ the hazard for the primary outcome decreases by 3.5% (Exp(B): 0.965; 95% CI:0.936–0.996) (Table 2). There was no evidence for an association of FiO₂ mean with recurrence-free survival in patients undergoing PC surgery (B = -0.01; Exp(B) = 0.990; CI:0.975–1.01; p = 0.217) (Table 3). Because the HC group consists of 27 patients only, it was not considered suitable for an individual Cox regression analysis.

TABLE 2

Table 2. Independent effects of FiO₂ on recurrence-free survival in patients with CRC.

TABLE 3

Table 3. Independent effects of FiO₂ on recurrence-free survival in patients with PC.

Secondary Endpoints

We examined 1-year and 5-year survival rates in patients with CRC, PC, and HC separately. In CRC patients, 1-year survival was 100% in both the low- and the high-FiO₂ group. After 5 years, five out of 203 patients had died (5-year survival 96.2%) in the low-FiO₂ group, whereas eight out of 202 patients had died in the high-FiO₂ group (5-year survival 94.6%). In PC patients, 39 out of 326 patients had died after 1 year (1-year survival 87.9%) in the low-FiO₂ group, whereas in the high-FiO₂ group 43 out of 326 patients had died (1-year survival 86.7%). After 5 years, 188 patients in the low-FiO₂ group had died (5-year survival 36.0%) vs. 183 patients in the high-FiO₂ group (5-year survival 38.5%). In HC patients, 1-year and 5-year survival was 100% in both the low-and the high-FiO₂ group. Neither 1- nor 5-year survival was different between the entity-controlled low-FiO₂ and entity-controlled high-FiO₂ group (p = 0.525) (Table 4).

TABLE 4

Table 4. Secondary outcome analysis.

Cardiovascular events (5 vs. 5, low-vs. high-FiO₂, p = 1) and incidence of sepsis (5 vs. 6, low- vs. high-FiO₂, p = 0.76) did not differ between groups. There was no difference in the rate of SSI (61 vs. 55, low-vs. high-FiO₂, p = 0.556), and the occurrence of reoperations was not different (40 vs. 36, p = 0.634, low-vs. high-FiO₂) (Table 4).

Discussion

In this retrospective exploratory study, we demonstrated in a real-world setting that higher intraoperative FiO₂ during abdominal cancer surgery was associated with better recurrence-free survival. In CRC surgery, higher FiO₂ was independently associated with increased recurrence-free survival. The hazard for the primary outcome decreased by 3.5% with every 1% increase in FiO₂. In PC surgery, we did not observe a significant effect and we did not find differences in any of the secondary endpoints.

The patient cohort under investigation had undergone surgery before the first WHO recommendation advocating supplemental oxygen for prevention of SSI (13) was published. Therefore, the decision for a specific FiO₂ was a clinical decision mainly based on the patients' respiratory function and the anesthetists' preference.

Oxygen has known pro- and anticarcinogenic effects. Hyperoxia may not only cause direct cell damage through the generation of reactive oxygen species (ROS) but also mediates cancerous effects (12, 23, 24), such as promotion of proliferation, invasiveness, angiogenesis, and metastasis. Interestingly, ROS generation may be accelerated under hyperoxia and also hypoxia (14). In addition, hypoxia can lead to organ dysfunction, lactic acidosis, cell death (25), and an increased expression of the hypoxia-inducible factor 1 (HIF-1) (26, 27) an intrinsic survival factor of tumor cells. Therefore, hypoxia can induce a vast number of gene products that control neovascularization, cell survival, energy metabolism, intracellular pH, and cell migration and are often associated with increased tumor aggressiveness, therapeutic resistance, and mortality (26, 28–31).

In clinical studies, evidence for FiO₂-mediated effects associated with long-term outcome after abdominal cancer surgery is sparse and controversial. In a post-hoc analysis of the PROXI trial, cancer-free survival was significantly shorter in the high oxygen group (12). In line, after a median follow-up of 2.3 years, a subsequent analysis of the same trial found increased long-term mortality in patients receiving 80% oxygen during cancer surgery (11). Contrarily, authors of other post-hoc analysis, combining mortality data from different RCTs, found that there was neither a difference in long-term mortality nor did they find differences in overall survival for patients randomly assigned to 30% vs. 80% FiO₂ (32, 33). The median follow-up was 12.8 (3.8, 13.6) years in the trial by Greif, 4.3 (3.6, 4.8) years in the trial by Kurz, and 3.2 (0.5, 4.9) years in the study by Jiang (1, 33, 34). This is in line with our finding that overall survival did not differ between high and low FiO₂ groups with a median follow-up of 3.28 (1.68, 4.97) years. Although FiO₂ appears to affect cancer recurrence, follow-up in our study might have been too short to observe effects on mortality after recurrence. Also, overall survival did not differ between the two groups investigated here, probably because overall survival depends on a variety of other factors not assessed in this study.

In most prospective studies, comparing different FiO₂ concentrations, patients were randomized for either 30 or 80% FiO₂. However, both targets have been accused to cause considerable side effects. Outside of clinical trials and before guidelines advocating high levels of supplemental oxygen were published, most anesthetists chose moderate FiO₂ levels between the high and low extremes. As a result, in our retrospective study, mean FiO₂ levels in the low- and high-FiO₂ groups were closer together than in other studies. Importantly, our institutional standards suggest avoiding not only hypoxia but also hyperoxia as both conditions might cause adverse events.

Pro and anticarcinogenic effects of oxygen might explain why, on one hand, 80% FiO₂ has adverse effects over 30% FiO₂ in some studies, but on the other hand, in our study, FiO₂ in the range of 50% compared with lower FiO₂ concentrations was beneficial with regard to recurrence-free survival. It is conceivable that the optimal FiO₂ for tumor surgery patients is neither met with an FiO₂ of 30% nor 80%. In fact, the association of FiO₂ or paO₂ respectively and recurrence-free survival may follow a V-shaped curve.

Oxygen related effects in tumor biology may also differ for distinct types of tumors. The association of tumor-associated transcription factors and tumor progress varies among different tumor entities (26). We included patients with CRC, PC, and HC. We demonstrated an independent association of FiO₂ with recurrence-free survival for CRC surgery patients but not for patients undergoing PC surgery. Interestingly, Podolyak et al. and Jiang et al. who did not find differences regarding cancer-free survival investigated only patients with elective colectomy in their post-hoc analysis, including RCTs (32, 33). In the post-hoc analysis of the PROXI trial, about half the patients underwent colorectal surgery (12). A subgroup analysis for non-colorectal procedures was not conducted, although cancer histology was considered (12).

Additional adverse effects of high-FiO₂ affecting the cardiovascular and respiratory systems have been reported in the literature. Hyperoxia induces increased peripheral vascular resistance, promotes reduced cardiac output, and mediates coronary vasoconstriction (14, 35). A post-hoc analysis of the PROXI-trial showed that patients with a FiO₂ of 80% had a significantly increased risk of myocardial infarction, acute coronary syndrome, or death (36). Contrary, the authors of a systematic review and meta-analysis concluded, based on 17 RCTs and two non-randomized studies, that perioperative supplemental oxygen was not associated with relevant complications (10). Consistent with this report, our analysis did not reveal differences for secondary cardiovascular endpoints or redo surgery.

WHO, ACS (American College of Surgeons), and CDC (Centers for Disease Control and Prevention) recommends supplemental oxygen with the aim to prevent SSI. In our study, SSI did not differ between the high- and low-FiO₂ groups. One could argue that the FiO₂ in the high-FiO₂ group was not sufficiently high to prevent SSI. However, the incidence of SSI reported in this study is lower than reported in most of the RCTs testing different oxygen levels in abdominal cancer surgery patients.

Our study has some limitations that need to be addressed. We performed a retrospective, single-center study with a limited set of exemplary tumor entities. The number of individuals included in the analysis was limited by the availability of digitalized anesthesia records, and only patients recruited in the surgical databases could be analyzed. The choice of FiO₂ values was not standardized and the patients were equally split into the low- and high-FiO₂ groups. The patients' intraoperative FiO₂ levels were compared by the calculation of the individual mean FiO₂, but the duration of exposure and individual dose during surgery were not included in this calculation. A consequence of the retrospective nature of our study is that we do not have full control over confounders. As tumor entity itself affects outcome, and we conducted an analysis stratified for entities and performed a cox regression analysis to control for confounders. However, we cannot fully exclude, that additional confounders affected findings reported in this study.

In conclusion, we demonstrate that, within a moderate range of FiO₂, higher FiO₂ during abdominal cancer surgery was associated with longer recurrence-free survival. In colorectal cancer surgery, increased FiO₂ was independently associated with increased recurrence-free survival. The findings will be instrumental for designing prospective studies delineating effects of certain FiO₂ on cancer development and progression for specific patient populations. Until definite evidence from large-scale randomized controlled trials is available, anesthesiologist, in the absence of relevant clinical conditions warranting specific FiO₂ values, should aim for an intraoperative FiO₂ of 50% in abdominal cancer surgery as this might benefit oncological outcome.

Data Availability Statement

The data analyzed in this study is subject to the following licenses/restrictions: Datenschutzgrundverordnung. Requests to access these datasets should be directed to jan.larmann@med.uni-heidelberg.de.

Ethics Statement

The studies involving human participants were reviewed and approved by Ethics Committee of the Medical Faculty of the Ruprecht-Karls-University, Heidelberg. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author Contributions

SD, VS, RK, and JL designed research and study protocol. SD, VS, LK, SK, and JL formal analysis. JL, SD, and VS statistical analysis. SK methodology and statistical consultation. SD, VS, RK, LK, KH, MS, TH, MB, and MW contributed to the data curation. SD, VS, and JL wrote the first draft of the manuscript. All authors critically reviewed and revised the manuscript and approved the final work.

Funding

This study was funded by institutional resources from the Departments of Anesthesiology and General, Visceral and Transplant Surgery. The position of LK was funded by the German Research Foundation (LA 2343/7-1) to JL. This research did not receive any other specific grants from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Acknowledgments

We gratefully acknowledge Ulf Hinz and Biljana Gigic, Department of General, Visceral and Transplant Surgery, University of Heidelberg, Heidelberg, Germany, for their support and co-operation in collecting the data. We also want to express our gratitude to Melanie Wickert, Department of Anesthesiology, University of Heidelberg, Heidelberg, Germany for her administrative support and manuscript editing.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.761786/full#supplementary-material

Abbreviations

ASA, American Society of Anesthesiologists physical status classification; B, Coefficient of variable; BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary Disease; CI, Confidence Intervals; CRC, Colorectal cancer; FAP, Familial Adenomatous Polyposis; FiO₂, Fraction of inspiratory oxygen; FFP, Fresh frozen plasma; HC, Hepatic cancer; HIF-1, Hypoxia-inducible factor 1; HR, Hazard Ratio; IORT, IntraOperative Radiation Therapy; paO₂, Arterial oxygen pressure; PC, Pancreatic cancer; PLT, Platelet concentrates; Q, Quartile; R 0, No residual tumor; R 1, Microscopic residual tumor; RBC, Red blood cells; RCT, Randomized controlled trial; ROS, Reactive Oxygen Species; SD, Standard Deviation; SE, Standard Error; SSI, Surgical Site Infetions; TNM, Tumor, Node, Metastasis; TU, Transfusion units; UICC, Tumor classification according to the Union for International Cancer Control; WHO, World-Health-Organization.

References

1. Greif R, Akça O, Horn EP, Kurz A, Sessler DI. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. N Engl J Med. (2000) 342:161–7. doi: 10.1056/NEJM200001203420303

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Qadan M, Akça O, Mahid SS, Hornung CA, Polk HC. Perioperative supplemental oxygen therapy and surgical site infection: a meta-analysis of randomized controlled trials. Arch Surg. (2009) 144:359–66. doi: 10.1001/archsurg.2009.1

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Pryor KO, Fahey TJ, Lien CA, Goldstein PA. Surgical site infection and the routine use of perioperative hyperoxia in a general surgical population: a randomized controlled trial. Jama. (2004) 291:79–87. doi: 10.1001/jama.291.1.79

PubMed Abstract | CrossRef Full Text | Google Scholar

4. de Jonge S, Egger M, Latif A, Loke YK, Berenholtz S, Boermeester M, et al. Effectiveness of 80% vs 30-35% fraction of inspired oxygen in patients undergoing surgery: an updated systematic review and meta-analysis. Br J Anaesth. (2019) 122:325–34. doi: 10.1016/j.bja.2018.11.024

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Ban KA, Minei JP, Laronga C, Harbrecht BG, Jensen EH, Fry DE, et al. American college of surgeons and surgical infection society: surgical site infection guidelines, 2016 update. J Am Coll Surg. (2017) 224:59–74. doi: 10.1016/j.jamcollsurg.2016.10.029

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Berríos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, et al. Centers for disease control and prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. (2017) 152:784–91. doi: 10.1001/jamasurg.2017.0904

PubMed Abstract | CrossRef Full Text | Google Scholar

7. WorldHealthOrganization. Global Guidelines for the Prevention of Surgical Site Infection. © World Health Organization (2018).

Google Scholar

8. Cohen B, Schacham YN, Ruetzler K, Ahuja S, Yang D, Mascha EJ, et al. Effect of intraoperative hyperoxia on the incidence of surgical site infections: a meta-analysis. Br J Anaesth. (2018) 120:1176–86. doi: 10.1016/j.bja.2018.02.027

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Smith BK, Roberts RH, Frizelle FA. O(2) No Longer the Go(2): a systematic review and meta-analysis comparing the effects of giving perioperative oxygen therapy of 30% FiO(2) to 80% FiO(2) on surgical site infection and mortality. World J Surg. (2020) 44:69–77. doi: 10.1007/s00268-019-05224-3

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Mattishent K, Thavarajah M, Sinha A, Peel A, Egger M, Solomkin J, et al. Safety of 80% vs 30-35% fraction of inspired oxygen in patients undergoing surgery: a systematic review and meta-analysis. Br J Anaesth. (2019) 122:311–24. doi: 10.1016/j.bja.2018.11.026

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Meyhoff CS, Jorgensen LN, Wetterslev J, Christensen KB, Rasmussen LS. Increased long-term mortality after a high perioperative inspiratory oxygen fraction during abdominal surgery: follow-up of a randomized clinical trial. Anesth Analg. (2012) 115:849–54. doi: 10.1213/ANE.0b013e3182652a51

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Meyhoff CS, Jorgensen LN, Wetterslev J, Siersma VD, Rasmussen LS. Risk of new or recurrent cancer after a high perioperative inspiratory oxygen fraction during abdominal surgery. Br J Anaesth. (2014) 113:i74–81. doi: 10.1093/bja/aeu110

PubMed Abstract | CrossRef Full Text | Google Scholar

13. WorldHealthOrganization. Global Guidelines for the Prevention of Surgical Site Infection. Geneva, (2016).

Google Scholar

14. Martin DS, Grocott MPIII. Oxygen therapy in anaesthesia: the yin and yang of O2. Br J Anaesth. (2013) 111:867–71. doi: 10.1093/bja/aet291

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Cuschieri S. The STROBE guidelines. Saudi J Anaesth. (2019) 13:S31–s4. doi: 10.4103/sja.SJA_543_18

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. (1958) 53:457–81. doi: 10.1080/01621459.1958.10501452

CrossRef Full Text | Google Scholar

17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. (1966) 50:163–70.

PubMed Abstract | Google Scholar

18. Cox DR. Regression Models and Life-Tables. J R Stat Soc B. (1972) 34:187–220. doi: 10.1111/j.2517-6161.1972.tb00899.x

CrossRef Full Text | Google Scholar

19. Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf. (2016) 25:733–7. doi: 10.1002/pds.3945

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Klaiber U, Schnaidt ES, Hinz U, Gaida MM, Heger U, Hank T, et al. Prognostic factors of survival after neoadjuvant treatment and resection for initially unresectable pancreatic cancer. Ann Surg. (2021) 273:154–62. doi: 10.1097/SLA.0000000000003270

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Strobel O, Hank T, Hinz U, Bergmann F, Schneider L, Springfeld C, et al. Pancreatic cancer surgery: the new r-status counts. Ann Surg. (2017) 265:565–73. doi: 10.1097/SLA.0000000000001731

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Ulrich CM, Gigic B, Böhm J, Ose J, Viskochil R, Schneider M, et al. The colocare study: a paradigm of transdisciplinary science in colorectal cancer outcomes. Cancer Epidemiol Biomarkers Prev. (2019) 28:591–601. doi: 10.1158/1055-9965.EPI-18-0773

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Selvendiran K, Kuppusamy ML, Ahmed S, Bratasz A, Meenakshisundaram G, Rivera BK, et al. Oxygenation inhibits ovarian tumor growth by downregulating STAT3 and cyclin-D1 expressions. Cancer Biol Ther. (2010) 10:386–90. doi: 10.4161/cbt.10.4.12448

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Nishida N, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, et al. Reactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesis. Dig Dis. (2013) 31:459–66. doi: 10.1159/000355245

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Schneider M, Weitz J. Acute oxygen deprivation and hypoxia tolerance. Dtsch Med Wochenschr. (2008) 133:2168–72. doi: 10.1055/s-0028-1091258

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Mabjeesh NJ, Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol. (2007) 22:559–72.

PubMed Abstract | Google Scholar

27. Ni J, Wang X, Stojanovic A, Zhang Q, Wincher M, Bühler L, et al. Single-Cell RNA sequencing of tumor-infiltrating NK cells reveals that inhibition of transcription factor HIF-1α unleashes NK cell activity. Immunity. (2020) 52:1075–87.e8. doi: 10.1016/j.immuni.2020.05.001

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol. (2006) 59:15–26. doi: 10.1016/j.critrevonc.2005.12.003

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. (2003) 3:721–32. doi: 10.1038/nrc1187

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem. (2009) 107:1053–62. doi: 10.1002/jcb.22214

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Milano M, Schneider M. EPO in cancer anemia: benefits and potential risks. Crit Rev Oncol Hematol. (2007) 62:119–25. doi: 10.1016/j.critrevonc.2006.11.011

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Podolyak A, Sessler DI, Reiterer C, Fleischmann E, Akça O, Mascha EJ, et al. Perioperative supplemental oxygen does not worsen long-term mortality of colorectal surgery patients. Anesth Analg. (2016) 122:1907–11. doi: 10.1213/ANE.0000000000001316

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Jiang Q, Kurz A, Zhang X, Liu L, Yang D, Sessler DI. Supplemental intraoperative oxygen and long-term mortality: subanalysis of a multiple crossover cluster trial. Anesthesiology. (2021) 134:709–21. doi: 10.1097/ALN.0000000000003694

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Kurz A, Fleischmann E, Sessler DI, Buggy DJ, Apfel C, Akça O. Effects of supplemental oxygen and dexamethasone on surgical site infection: a factorial randomized trial. Br J Anaesth. (2015) 115:434–43. doi: 10.1093/bja/aev062

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Wijesinghe M, Perrin K, Ranchord A, Simmonds M, Weatherall M, Beasley R. Routine use of oxygen in the treatment of myocardial infarction: systematic review. Heart. (2009) 95:198–202. doi: 10.1136/hrt.2008.148742

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Fonnes S, Gögenur I, Søndergaard ES, Siersma VD, Jorgensen LN, Wetterslev J, et al. Perioperative hyperoxia - Long-term impact on cardiovascular complications after abdominal surgery, a post hoc analysis of the PROXI trial. Int J Cardiol. (2016) 215:238–43. doi: 10.1016/j.ijcard.2016.04.104

PubMed Abstract | CrossRef Full Text | Google Scholar